Previous 10 | Next 10 |
2023-08-17 12:16:09 ET Engaging in the world of low-cost stocks often referred to as penny stocks , is appealing to those looking to capitalize on the potential upsides of the stock market. These stocks, priced below $5, are known for their intrinsic risk. They’re also known for ...
2023-08-10 13:25:55 ET Gainers: WeWork ( WE ) +87% . Capri Holdings Limited ( CPRI ) +56% . Black Spade Acquisition ( BSAQ ) +58% . Edible Garden AG Incorporated ( EDBL ) +43% . Lion Group Holding Ltd. ( LGHL ) +37% . Precige...
2023-08-10 10:27:32 ET Gainers: LifeMD ( LFMD ) +20% . Precigen ( PGEN ) +19% . Repare Therapeutics ( RPTX ) +16% . Cosmos Health ( COSM ) +13% . GoodRx Holdings ( GDRX ) +13% . Losers: Galera Therapeutics ( GRTX ) -...
2023-08-09 15:03:06 ET Precigen, Inc. (PGEN) Q2 2023 Earnings Conference Call August 09, 2023 08:30 AM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Executive Officer Harry Thomasian - Chief Fin...
2023-08-09 15:01:02 ET More on Precigen Unraveling The Promise Of Precigen: Biotech Innovations Amid Financial Challenges Precigen gains on FDA Breakthrough Therapy Designation Precigen gets IND clearance for phase 2 trial of cervical cancer immunotherapy Pre...
2023-08-09 08:02:24 ET Precigen press release ( NASDAQ: PGEN ): Q2 GAAP EPS of -$0.08 beats by $0.02 . Revenue of $1.77M (-39.2% Y/Y) misses by $0.41M . Cash, cash equivalents, short-term and long-term investments totaled $95.6 million as of June 30, 2023; cash...
Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025 PR Newswire – The FDA confirmed that the ongoing Phase 1/2 single arm study ...
Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval PR Newswire – FDA confirmed that the ongoing Phase 1/2 single arm study will serve as pivotal and n...
2023-08-08 12:44:42 ET Precigen ( NASDAQ: PGEN ) is scheduled to announce Q2 earnings results on Wednesday, August 9th, before market open. The consensus EPS Estimate is -$0.10 and the consensus Revenue Estimate is $2.18M (-25.1% Y/Y). For further details see: Pr...
2023-08-08 10:46:10 ET Major earnings expected before the bell on Wednesday include: Brookfield Asset Management ( BAM ) 3D Systems ( DDD ) PENN Entertainment ( PENN ) Roblox ( RBLX ) Sony Group ( SONY ) For further details see: Notable ea...
News, Short Squeeze, Breakout and More Instantly...
2024-06-03 14:30:04 ET Stifel Nicolaus analyst issues MARKET OUTPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst co...
2024-06-03 14:30:03 ET JMP Securities analyst issues UNDERPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Underperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst consensus : B...
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire – Phase 1/2 pivotal study met the primary safety and efficacy endpoints ...